GYNECOLOGY (uterine, ovary, cervix)
PROTOCOL DETAILS |
PROTOCOL TITLE |
DISEASE SITE |
Principal Investigator:
Peter Argenta
Contact:
Sharon Donnelly or
Marva Bohen
info@cancer.umn.edu
(612) 624-2620
|
A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxrorubicin (Doxil/Caelyx) in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer (Study No. CEPO906A2303) |
Ovarian, Fallopian, Primary Peritoneal |
Principal Investigator:
Peter Argenta
Contact:
Deborah Biegert
biege001@umn.edu
612-624-8647
|
WCC #49 Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma |
Ovarian |
Principal Investigator:
Linda Carson
Contact:
Suann Mitchell
mitch016@umn.edu
612-624-1919
|
GOG 0212: A Randomized Phase Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) Versus No Treatment Until Documented Relapse in Women with Response to Primary Platinum/Taxane Chemotherapy |
|
Principal Investigator:
Linda Carson
Contact:
Suann Mitchell
mitch016@umn.edu
612-624-1919
|
WCC 34 A Phase I Study of Adjuvant Topotecan and Cisplatin with Concurrent Radiation Therapy for Advanced Cervical Cancer |
Cervical, Uterine |
Principal Investigator:
Levi Downs
Contact:
Sharon Donnelly or
Marva Bohen
info@cancer.umn.edu
(612) 624-2620
|
WCC #45: Prolonged Venous Thromboembolism Prophylaxis with Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial |
|
Principal Investigator:
Levi Downs
Contact:
Sharon Donnelly or
Marva Bohen
info@cancer.umn.edu
(612) 624-2620
|
A Multi-Center, Double-Blinded, Randomized, Placebo-Controlled Study of ZYC101a in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN2/3) of the Uterine Cervix |
Uterine, Cervical |
Principal Investigator:
Levi Downs
Contact:
Sharon Donnelly or
Marva Bohen
info@cancer.umn.edu
(612) 624-2620
|
WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer |
Cervical |
Principal Investigator:
Melissa Geller
Contact:
Deborah Biegert
biege001@umn.edu
612-624-8647
|
WCC 40: A Phase II Study of Carboplatin and Weekly Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women with Advanced Staged Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma for High Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced |
Ovarian, Fallopian, Primary Peritoneal |
Principal Investigator:
Melissa Geller
Contact:
Deborah Biegert
biege001@umn.edu
612-624-8647
|
WCC 38 A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy then Cobnsolidation Chemotherapy with Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer |
Uterine |
Principal Investigator:
Patricia Judson
Contact:
Suann Mitchell
mitch016@umn.edu
612-624-1919
|
GOG 209 Randomized Phase III Trial of Doxorubicin/ Cisplatin/ Paclitaxel and G-CSF vs. Carboplatin/ Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer |
Uterine |
Principal Investigator:
Patricia Judson
Contact:
Melissa Spence
spenc206@umn.edu
(612) 624-2620
|
A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma (AVF4095g) |
Ovarian, Fallopian, Primary Peritoneal |
Principal Investigator:
Patricia Judson
Contact:
Suann Mitchell
mitch016@umn.edu
612-624-1919
|
GOG 0218: A Phase III Trial of Carboplatin and Paclitaxel plus Placebo Versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab followed by Placebo versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Peritoneal Primary Cancer |
Ovarian, Primary Peritoneal |
Principal Investigator:
Chung Kyu Lee
Contact:
Diane Mosel
dmosel@umphysicians.umn.edu
612-626-2627
|
RTOG C-0116: A Two-part Phase I/II Study of Extended Field External Irradiation and Interacavitary Brachytherapy Combined with Chemotherapy (Weekly Cisplatin-Arm 1) and Amifostine (Weekly Cisplatin and Amifostine-Arm 2) in Carcinoma of the Cervix with Positive Para-Aortic or High Common Iliac Lymph Nodes |
Cervical, Uterine |
Return to: Medical School : Academic Health Center : myU : U of M Home
